Holdingsas Novo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Holdingsas novo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Holdingsas Novo Today - Breaking & Trending Today

Spruce Biosciences, Inc. (NASDAQ:SPRB) Shares Purchased by AIGH Capital Management LLC

AIGH Capital Management LLC grew its holdings in shares of Spruce Biosciences, Inc. (NASDAQ:SPRB – Free Report) by 75.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,123,863 shares of the company’s stock after acquiring an additional 912,863 shares during the period. […] ....

Leerink Partnrs , Royal Bank , Spruce Biosciences Inc , Aigh Capital Management , Holdingsas Novo , Exchange Commission , Worth Venture Partners , Spruce Biosciences Company Profile , Capital Management , Spruce Biosciences , Free Report , Venture Partners , Get Free Report , Visit Holdingschannel , Spruce Biosciences Daily ,

Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Consensus Rating of "Hold" by Analysts

Spruce Biosciences, Inc. (NASDAQ:SPRB – Get Free Report) has been assigned a consensus rating of “Hold” from the eight ratings firms that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year target price […] ....

Leerink Partnrs , Capital Management , Investment Company Inc , Spruce Biosciences Inc , Securities Exchange Commission , Acadian Asset Management , Worth Venture Partners , Holdingsas Novo , Spruce Biosciences , Get Free Report , Exchange Commission , Venture Partners , Asset Management , Superstring Capital Management , Get Free , Spruce Biosciences Daily ,

HC Wainwright Raises IO Biotech (NASDAQ:IOBT) Price Target to $12.00

IO Biotech (NASDAQ:IOBT – Free Report) had its price objective increased by HC Wainwright from $8.00 to $12.00 in a research report released on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for IO Biotech’s Q2 2024 earnings at ($0.31) EPS, Q3 2024 earnings at […] ....

Stonepine Capital Management , Armistice Capital , Io Biotech Inc , Health Sciences , Holdingsas Novo , Vivo Capital , Free Report , Get Free Report , Capital Management ,

IO Biotech (NASDAQ:IOBT) Price Target Raised to $12.00 at HC Wainwright

IO Biotech (NASDAQ:IOBT) Price Target Raised to $12.00 at HC Wainwright
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Vivo Capital , Io Biotech Inc , Health Sciences , Io Biotech Company Profile , Stonepine Capital Management , Securities Exchange Commission , Holdingsas Novo , Armistice Capital , Free Report , Stock Down , Get Free Report , Exchange Commission , Capital Management ,

JPMorgan Chase & Co. Lowers Metagenomi (NASDAQ:MGX) to Neutral

JPMorgan Chase & Co. lowered shares of Metagenomi (NASDAQ:MGX – Free Report) from an overweight rating to a neutral rating in a report published on Thursday, MarketBeat.com reports. They currently have $6.00 target price on the stock, down from their prior target price of $16.00. A number of other equities research analysts have also issued […] ....

United States , Jpmorgan Chase Co , Jefferies Financial Group , Metagenomi Inc , Holdingsas Novo , Wells Fargo Company , Free Report , Financial Group , Chardan Capital , Moderate Buy , Get Free Report , Metagenomi Daily , Nasdaq Mgx , Jpmorgan Chase Co ,